# US 2003/0223972 A1 · Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0223972 A1
- Document ID: US20030223972A1
- Status: Published application
- Kind: A1
- Application number: 10/368,810
- Filed: 2003-02-14
- Published: 2003-12-04
- Earliest claimed: 2002-02-15
- Inventors: Steven A. Goldman; Neeta Singh Roy; Martha Windrem
- Web page: https://patentgrep.com/patent/US20030223972A1

## CPC

- C12N 5/0622: {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0623: {Stem cells}
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- C12N 5/0618: {Cells of the nervous system}
- C12N 5/0619: {Neurons}
- C12N 2510/00: Genetically modified cells
- G01N 33/56966: {Animal cells}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This further aspect of the present invention involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population. Oligodendrocyte progenitor cells are then separated from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells.

## Claims

### Claim 1

A method of remyelinating demyelinated axons comprising:
treating the demyelinated axons with oligondendrocyte progenitor cells under conditions which permit remyelination of the axons.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said treating is carried out by transuterine fetal intraventricular injection, intraventricular or intraparenchymal injections, intraparenchymal injections into adult and juvenile subjects, or intravascular administration.

### Claim 3

A method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes comprising:
administering to the subject oligondendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the method is used to treat a subject with a condition mediated by a loss of oligodendrocytes.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the method is used to treat a subject with a condition mediated by a loss of myelin.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the condition is an ischemic demyelination condition.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the ischemic demyelination condition is selected from the group consisting of cortical stroke, Lacunar infarct, post-hypoxic leukoencephalopathy, diabetic leukoencephalopathy, and hypertensive leukoencephalopathy.

### Claim 8 (depends on 5)

The method according to claim 5, wherein the condition is an inflammatory demyelination condition.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the inflammatory demyelination condition is selected from the group consisting of multiple sclerosis, Schilder's Disease, transverse myelitis, optic neuritis, post-vaccination encephalomyelitis, and post-infectious encephalomyelitis.

### Claim 10 (depends on 5)

The method according to claim 5, wherein the condition is a pediatric leukodystrophy.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the pediatric leukodystrophy condition is selected from the group consisting of a lysosomal storage disease, Cavavan's Disease, Pelizaeus-Merzbacher Disease, and Crabbe's Globoid body leukodystrophy.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the pediatric leukodystrophy condition is Tay-Sachs Disease.

### Claim 13 (depends on 5)

A method according to claim 5, wherein the condition is mucopolysaccharidosis.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the condition is Sly's Disease.

### Claim 15 (depends on 5)

The method according to claim 5, wherein the condition is perinatal germinal matrix hemorrhage, periventricular leukoinalacia, or cerebral palsy.

### Claim 16 (depends on 5)

The method according to claim 5, wherein the condition is a radiation-induced condition.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the radiation-induced condition is radiation-induced leukoencephalopathy or radiation-induced myelitis.

### Claim 18 (depends on 5)

The method according to claim 5, wherein the condition is an etiology causing sub-cortical leukoencephalopathy, said etiology being HIV/AIDS, head trauma, or multi-infarct states.

### Claim 19 (depends on 3)

The method according to claim 3, wherein said treating is carried out after administering radiation to the subject and before demyelination has occurred.

### Claim 20 (depends on 3)

The method according to claim 3, wherein the subject is a human.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the subject is a post-natal human.

### Claim 22 (depends on 20)

The method according to claim 20, wherein the subject is an adult human.

### Claim 23 (depends on 3)

The method according to claim 3, wherein the method is carried out in the brain.

### Claim 24 (depends on 3)

The method according to claim 3, wherein the method is carried out in the spinal cord.

### Claim 25

An in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types, said method comprising:
removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population and
separating the oligodendrocyte progenitor cells from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells.

### Claim 26 (depends on 25)

The method according to claim 25, wherein said separating oligodendrocyte progenitor cells comprises:
selecting a promoter which functions only in oligodendrocyte progenitor cells and not in the other cell types;
introducing a nucleic acid molecule encoding a fluorescent protein under control of said promoter into all cell types of said treated mixed population;
allowing only the oligodendrocyte progenitor cells, but not the other cell types, within said treated mixed population to express said fluorescent protein;
identifying cells of said treated mixed population of cell types that are fluorescent, which are restricted to oligodendrocyte progenitor cells; and
separating the fluorescent cells from said treated mixed population to form the enriched population of oligodendrocyte progenitor cells.

### Claim 27 (depends on 26)

The method according to claim 26, wherein said introducing comprises viral mediated transformation of all cell types of said treated mixed population containing other mammalian brain or spinal cord cell types.

### Claim 28 (depends on 27)

The method according to claim 27, wherein said viral mediated transformation comprises adenovirus mediated transformation, retrovirus-mediated transduction, lentivirus-mediated transduction, or adeno-associated virus-mediated transduction.

### Claim 29 (depends on 26)

The method according to claim 26, wherein said introducing comprises electroporation.

### Claim 30 (depends on 26)

The method according to claim 26, wherein said introducing comprises liposomal mediated transformation of all cell types of said treated mixed population containing other mammalian brain or spinal cord cell types.

### Claim 31 (depends on 26)

The method according to claim 26, wherein said separating the fluorescent cells comprises fluorescence activated cell sorting.

### Claim 32 (depends on 26)

The method according to claim 26, wherein said promoter is selected from the group consisting of a cyclic nucleotide phosphorylase I promoter, a myelin basic protein promoter, a JC virus minimal core promoter, a proteolipid protein promoter, a qk1 promoter, and a cyclic nucleotide phosphorylase II promoter.

### Claim 33 (depends on 25)

The method according to claim 25, wherein said separating oligodendrocyte progenitor cells comprises:
immunoseparating the oligodendrocyte progenitor cells.

### Claim 34 (depends on 33)

The method according to claim 33, wherein said immunoseparating is carried out by removing cells from the treated mixed population having an A2B5 antigen.

### Claim 35 (depends on 33)

The method according to claim 33, wherein said immunoseparating is carried out with a fluorescently labelled antibody which recognizes an antigen on the oligodendrocyte progenitor cells.

### Claim 36 (depends on 35)

The method according to claim 35, wherein said separating oligodendrocyte progenitor cells further comprises:
fluorescence activated cell sorting.

### Claim 37 (depends on 25)

The method according to claim 25, wherein said removing comprises:
selecting a promoter which functions only in neurons and neuronal progenitor cells;
introducing a nucleic acid molecule encoding a marker protein under control of said promoter into the mixed population;
allowing the neurons and neuronal progenitor cells to express the marker protein; and
separating the cells expressing the marker protein from the mixed population of cells, wherein said separated cells are the neurons and neuronal progenitor cells.

### Claim 38 (depends on 37)

The method according to claim 37, wherein said introducing comprises viral mediated transduction of the mixed population of cells.

### Claim 39 (depends on 38)

The method according to claim 38, wherein said viral mediated transduction comprises adenovirus-mediated transduction, retrovirus-mediated transduction, lentivirus-mediated transduction, or adeno-associated virus-mediated transduction.

### Claim 40 (depends on 37)

The method according to claim 37, wherein said introducing comprises electroporation.

### Claim 41 (depends on 37)

The method according to claim 37, wherein said introducing comprises biolistic transformation.

### Claim 42 (depends on 37)

The method according to claim 37, wherein said introducing comprises liposomal mediated transformation.

### Claim 43 (depends on 37)

The method according to claim 37, wherein the marker protein is a fluorescent protein and said separating comprises fluorescence activated cell sorting.

### Claim 44 (depends on 37)

The method according to claim 37, wherein the promoter is a Tα1 tubulin promoter, a MAP-1B promoter, an NCAM promoter, An HES-5 HLH promoter, an α-internexin promoter, or a GAP-43 promoter.

### Claim 45 (depends on 25)

The method according to claim 25, wherein the cell type is human.

### Claim 46 (depends on 45)

The method according to claim 45, wherein the human is an adult.

### Claim 47 (depends on 45)

The method according to claim 45, wherein the human is postnatal.

### Claim 48 (depends on 25)

The enriched population of oligodendrocyte progenitor cells produced according to the process of claim 25.
